Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology News Journal.
Press releases published on August 12, 2025

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio expanded • Leadership team …

Shawn McLevige Appointed as President of Woodward’s Aerospace Segment
FORT COLLINS, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ: WWD), a global leader in energy controls for aerospace and industrial markets, today announced key leadership changes aligned with the company’s continued focus on growth, …

First Lady Anna Stein, NCDHHS and Morse Clinics Celebrate First Mobile Opioid Treatment Program Unit in North Carolina
Raleigh, NC, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Credentialed media are invited to attend the unveiling of the first Mobile Opioid Treatment Program (OTP) unit in North Carolina. Mobile OTPs reduce barriers to participation in treatment by making it easier …

Urgently Announces Second Quarter 2025 Financial Results
ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today reported financial results for the second quarter ended June …

ImmuCell Announces Bank Debt Refinancing
PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

Rigetti Computing Reports Second Quarter 2025 Financial Results; Announces General Availability of its 36-Qubit Multi-Chip Quantum Computer
BERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the second quarter ended June 30, 2025. …

ARRAY Technologies, Inc. to Participate in Upcoming Investor Conferences and Events
ALBUQUERQUE, N.M., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software and services, today announced its attendance at the following …

Diginex Announces MOU for US$305m Acquisition of Findings, a leading cybersecurity and compliance automation company
LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) to acquire 100% of …

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and …

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support operations through …

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design …

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell …

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to begin enrolling …

Varonis to Present at Upcoming Investor Conference
MIAMI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conference: Citi's 2025 Global TMT Conference, September 2 – 5, in New York. The presentation …

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute …

Mobile Infrastructure Reports Second Quarter 2025 Financial Results
--Higher Contract Parking Volumes Reflect Positive Secular Growth Trends-- --Advancing Non-Core Asset Divestiture Strategy-- --Conference Call Will be Held Today at 4:30 PM ET-- CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mobile Infrastructure …

Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health …

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top- …

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Presented three abstracts at American Society of Gene …